Compare Live Nation Entertainment, Inc. (LYV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Live Nation Entertainment, Inc. trades at $170.33 (market cap $39.92B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.4× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LYV | ZBH | |
|---|---|---|
Market Cap | $39.92B | $16.95B |
Volume | 1,982,609 | 2,505,240 |
Sector | Media | Health |
52-Week High | $188.46 | $103.98 |
52-Week Low | $125.61 | $79.58 |
Typical Hold Time | 72 Days | 89 Days |
Enterprise Value | $42.13B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $171.34, up 0.29% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 earnings that beat expectations with EPS of $1.05 versus $0.66 expected, driven by strong attendance and record deferred revenue. Revenue for 2025 reached $25.20 billion, though net income margin narrowed to 1.96%. Analyst consensus is strongly bullish with 40 buy ratings and a $208.18 price target, reflecting optimism around live event demand.
The outlook for LYV remains positive given robust fan demand and strategic expansions, but high valuation multiples, debt levels, and regulatory scrutiny pose risks. Earnings visibility is supported by $6.4 billion in deferred revenue, though margin pressure and legal uncertainties could temper near-term gains. The stock offers growth exposure to the experience economy, yet investors should weigh execution risks against bullish analyst sentiment.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
